NAICS 541714 - Research and Development in Biotechnology encompasses scientific research and experimental development focused on innovative biotechnological processes, products, and technologies. This category covers advanced scientific investigations in areas such as genomics, molecular biology, genetic engineering, and specialized biomedical research. The work typically involves developing novel biological techniques, testing new therapeutic approaches, creating advanced diagnostic technologies, and exploring innovative applications of biological systems and mechanisms. The federal contract awards in this NAICS category demonstrate significant investment in cutting-edge biotechnology research across multiple federal agencies. Awards frequently originate from the National Institutes of Health, specifically institutes like NIAID, NHLBI, and NIDDK, with contract values ranging from approximately $5,000 to over $300 million. Common awardees include research universities (Stanford, Duke, University of California), biotechnology firms (Mission Bio, Illumina), and medical research institutions. Most awards are not set-aside, allowing broad competition, and performance locations are predominantly in academic and research settings across the United States. Contract types vary, including firm fixed-price, cost-reimbursement, and cost-sharing arrangements, with durations typically spanning 1-5 years. Recent federal contract opportunities reflect diverse biotechnological research priorities across government agencies. The Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health have solicited proposals for innovative research areas including quantum biology, AI-enabled drug discovery, radiation countermeasures, and advanced computational modeling of biological systems. Opportunities consistently seek to advance scientific understanding through development of novel technologies, diagnostic tools, therapeutic approaches, and research methodologies. Performance locations are primarily within U.S. research institutions, with a strong emphasis on solving complex scientific challenges in areas such as infectious diseases, medical countermeasures, genomics, and advanced biotechnological applications.
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
75N92019D00017 | Lovelace Biomedical Research Institute | $13.3m | 12/19/18 | 6/18/25 | 6/14/24 | |
75N92018D00007 | University Of Alabama At Birmingham | $6.6m | 7/1/18 | 6/30/24 | 7/11/24 | |
75N95021D00023 | Booz Allen Hamilton Inc. | $47.0m | 9/17/21 | 9/16/26 | 12/17/24 | |
75N95018D00023 | Rutgers, The State University | $19.7m | 9/19/18 | 9/20/22 | 2/15/24 | |
75A50120D00018 | Technical Resources International, Inc. | $400.0m | 9/28/20 | 9/27/25 | 9/3/24 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Definitive Contract 75A50124C00027 | Revvity Health Sciences, Inc. | $9.3m | 9/30/24 | 12/31/26 | 2/19/25 | |
Delivery Order 75N92019D00017-75N92020F00001 | Lovelace Biomedical Research Institute | $352.5k | 6/8/20 | 11/19/21 | 5/18/23 | |
Delivery Order 75N92018D00007-75N92020F00001 | University Of Alabama At Birmingham | $1.1m | 11/14/19 | 1/31/23 | 1/16/25 | |
Delivery Order 75N95021D00023-75N95021F00001 | Booz Allen Hamilton Inc. | $3.1m | 9/17/21 | 9/16/22 | 9/15/21 | |
Definitive Contract 75N95022C00041 | The Emmes Company LLC | $9.2m | 9/30/22 | 9/29/25 | 9/18/24 |
A Portfolio Platform of GovExec © 2025